PIPELINE
We develop treatments applicable across multiple neurodegenerative diseases to address urgent unmet need.
ALS = Amyotrophic lateral sclerosis, FTD = Frontotemporal Dementia, AD = Alzheimer's Disease, PN = Peripheral Neuropathy, PD = Parkinson's DiseasePROGRAMS
APRTX-001: a first-in-class molecule for targeted suppression of microglial-driven neuroinflammation.
CD33 is a critical regulator of inflammatory activity in the brain and spinal cord, modulating molecular signaling pathways that lead to suppression of microglial phagocytosis and induction of a pro-inflammatory glial phenotype. Its level is consistently elevated in tissues from patients with neurodegenerative diseases, including ALS, FTD, PD, and AD.
Inhibition of CD33 in human cells and naturally occurring loss-of-function variants in the general population provide greater resilience to neurodegenerative diseases, reduced neuroinflammation, and lower levels of key pathological biomarkers linked to neural aging and degeneration.
Aperture has identified a genetic link between CD33 and progression of severe neurodegenerative diseases, established novel humanized rodent models of CD33, and developed APRTX-001 as a potent modulator of CD33 activity.
APRTX-002 - APRTX-005: Undisclosed
PARTNERING
We are partnering to advance new medicines through clinical development, and unlock new genetic targets for neurological and inflammatory diseases.
Pharma partnerships to advance assets through clinical trials
Biotech partnerships to unlock delivery routes and disease indications
For licensing and partnership opportunities, please contact partnering@aperturetx.com